Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single Injection, Three Injection, Five Injection), By End-use (Hospitals, Orthopedic Clinics/ASCs), By Region (Asia Pacific, Europe), And Segment Forecasts, 2023 - 2030

Report Overview

The global viscosupplementation market size was estimated at USD 4.41 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 9.58% from 2023 to 2030. Viscosupplementation aims to alleviate joint pain and enhance the functional state of the knee. The growing incidence of osteoarthritis (OA) plays a significant role in driving the demand for viscosupplementation. Osteoarthritis, a chronic degenerative joint disease, is the primary cause of enduring disability. It typically emerges after the age of 30 and can progress to a disabling condition within a decade of diagnosis. In the United States, more than 32.5 million adults are affected by OA. According to the Global Burden of Disease Study 2019, the global prevalence of OA surged by 113.25%, rising from 247.51 million cases in 1990 to 527.81 million cases in 2019.

Furthermore, the market is anticipated to be propelled by the growing demand for non-surgical solutions for osteoarthritis, the prevalence of lifestyle-related conditions, and advancements in the development of therapies utilizing hyaluronic acid. The available viscosupplements have demonstrated clinical effectiveness and are established as the most efficient treatment option for knee osteoarthritis, thus stimulating market growth. The rising geriatric population is another factor boosting the market growth. According to the CDC data, nearly half (49.6%) of individuals aged 65 years or older have reported being diagnosed with arthritis by a medical professional. The demand for viscosupplementation is high among the geriatric population as it can relieve joint pain, enhance mobility, and offer a non-surgical alternative for managing osteoarthritis, ultimately leading to an improved quality of life for older individuals.

Moreover, the global reimbursement landscape is anticipated to become more favorable, ensuring the affordability of osteoarthritis treatments. In the United States, FDA-approved Class III medical devices like Orthovisc, Supartz Hyalgan, Synvisc, and others for managing knee pain caused by osteoarthritis receive reimbursement from Medicaid, Medicare, and various state healthcare programs. France also boasts a well-established reimbursement policy for viscosupplements. Out of the 13 products available for knee osteoarthritis treatment in France, 12 are reimbursed up to 65% by social security. These favorable reimbursement policies specifically targeted at the geriatric population are expected to create growth opportunities for key market players.

Furthermore, recent research and development advancements in the product pipeline are anticipated to impel the market growth over the forecast period. An example of this is the completion of clinical trials by Bone Therapeutics S.A. in April 2018 for their intra-articular injection JTA-004, specifically designed for knee osteoarthritis. Furthermore, the market is witnessing the introduction of new products that offer more effective results. For instance, in June 2019, Anika Therapeutics, Inc. showcased its innovative hyaluronic acid-based scaffold called Hyalofast for cartilage repair at the International Cartilage Regeneration and Joint Preservation Society (ICRS). These advancements in R&D and the introduction of novel products contribute to the expansion of the industry.

Product Insights

Based on the products, the market is divided into single injections, three injections, and five injections. The three-injection viscosupplementation procedure segment dominated the market in 2022 with a revenue share of 43.1%. Three-injection procedures are the most preferred method to treat osteoarthritis due to their effectiveness. Medical practitioners generally prefer three-injections to help avoid total knee replacement surgery in case of osteoarthritis. In addition, the availability of multiple three-injection segments in the market is contributing to the market share. Furthermore, many clinical trials have been approved and shown positive results regarding their three-injection procedures to treat osteoarthritis.

This, along with investments in R&D and the growing need to treat the ailment is anticipated to drive the market growth over a forecast period. The single-injection segment is expected to register the fastest growth rate over the forecast period. These injections are relatively new in the market but show promising growth owing to a shorter regimen, reduced hospital visits, and fewer adverse effects and associated pain. Gel-One by Zimmer Biomet is the first low-volume viscosupplement available in the single-injection formula. It is intended for patients that do not respond to other conservative treatments.

End-use Insights

Based on end-uses, the market is divided into hospitals and orthopedic clinics/ambulatory surgical centers (ASCs). The orthopedic clinics and ambulatory surgical centers segment dominated the market in 2022 with a revenue share of 62.3% due to the high demand for outpatient surgeries. Orthopedic clinics are dedicated to the care of the musculoskeletal system. This includes the treatment of surgical and nonsurgical problems involving joints, bones, ligaments, muscles, spine, and nerves. The increasing prevalence of osteoarthritis among the geriatric population is one of the major factors expected to contribute to the growth of this segment.

The segment is also anticipated to grow at the fastest rate as ASCs can perform same-day surgeries for ACL surgery, hip, knee, & shoulder replacements, and others. These surgeries are less complicated and require little to no hospitalization. Also, it allows orthopedic clinics to accept more patients per day. However, hospitals are forecasted to continue to grow in the coming years due to advancements in medical technology, causing a recent emergence in multispecialty hospitals. According to the Global RA Network, more than 350 million people had arthritis in 2021, across the globe. This staggering number is growing each year, due to the growing older demographic. As a result, the growth of clinics and hospitals will likely continue.

Regional Insights

Asia Pacific held the largest market share of 45.57% in 2022. the presence of geriatric population, which is susceptible to osteoarthritis, is one of the major factors driving the growth of the market growth in this region. Also, various initiatives undertaken to strengthen the market are driving its growth. For instance, In April 2022, Juniper Biologics and Kolon Life entered into a licensing agreement for the development and commercialization of TissueGene-C low dose, an investigational therapy for knee osteoarthritis.

It is administered as a single intra-articular injection and does not require surgery. As per the agreement, Juniper is responsible for the development and marketing of gene therapy to medical professionals and hospitals in the Asia Pacific region. Europe is anticipated to register the fastest growth rate over a forecast period due to factors, such as the growing geriatric population and increased investments by market players. Osteoporosis affects more than 2.5 million women in the UK and France every year.

Key Companies & Market Share Insights

Medical technology advancements, accelerated trial approvals, new product launches, mergers & acquisitions, collaborations, and other inventions have been adopted by major companies who either want to enter the global industry or want to maintain their position in the market. In December 2021, Avanos Medical, a med-tech company acquired OrthogenRx, Inc., a leader in the viscosupplementation therapies industry for the treatment of knee osteoarthritis. Avanos utilizes the benefits of FDA-approved GenVisc850 and TriVisc. Some of the prominent players in the global viscosupplementation market include:

• DePuy Synthes

• Fidia Farmaceutici S.p.A

• Sanofi

• Smith & Nephew PLC

• Anika Therapeutics, Inc.

• Seikagaku Corp.

• Zimmer Biomet

• Ferring Pharmaceuticals B.V.

• Lifecore Biomedical

• LG Life Sciences Ltd.

• F.Hoffmann-La Roche Ltd.

Viscosupplementation Market Report Scope

Global Viscosupplementation Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global viscosupplementation market report based on product, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Single Injection

  • Three Injection

  • Five Injection

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Orthopedic Clinics/ASCs

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • France

    • Germany

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait